Abstract
Asthma is a chronic inflammatory disorder of the respiratory system characterised by recurrent “reversible” obstruction of the airwflow in the airway. Various agents have been used in the treatment of asthma out of which inhaled beta-2 agonists have been mainstay of bronchodilator therapy of asthma for more than 40 years. Short-acting beta-2 agonists are still recommended for relieving the acute episode of bronchoconstriction. Long-acting beta-2 agonists (LABAs), alongwith inhaled corticosteroides are used as a first line anti-inflammatory therapy. The recent evidence suggested that the ability of short-acting and long-acting beta-2 agonists to protect the airways against bronchoconstrictor stimuli and to promote bronchodilatation may be partially lost with time following long-term use. The long-term use of beta-2 agonist is associated with an increased incidence of asthma exacerbations and other markers of morbidity and mortality. In this article, we try to address some of the current controversies as well as propose various mechanisms behind beta-2 agonist induced morbidity and mortality in asthmatic patients. On the basis of this article, we recommended that clinicians have to refine the use of beta-2 agonists in asthma management guidelines to avoid the beta-2 agonists induced asthma exacerbations.
Keywords: Asthma, long-acting beta-2 agonists, short-acting beta-2 agonists
Current Respiratory Medicine Reviews
Title: Beta-2 Agonists in Asthma: Medicine or Murderer?
Volume: 4 Issue: 3
Author(s): Vasanti Patel, Dipika Patel, Natvarbhai Patel and Priyanshee Gohil
Affiliation:
Keywords: Asthma, long-acting beta-2 agonists, short-acting beta-2 agonists
Abstract: Asthma is a chronic inflammatory disorder of the respiratory system characterised by recurrent “reversible” obstruction of the airwflow in the airway. Various agents have been used in the treatment of asthma out of which inhaled beta-2 agonists have been mainstay of bronchodilator therapy of asthma for more than 40 years. Short-acting beta-2 agonists are still recommended for relieving the acute episode of bronchoconstriction. Long-acting beta-2 agonists (LABAs), alongwith inhaled corticosteroides are used as a first line anti-inflammatory therapy. The recent evidence suggested that the ability of short-acting and long-acting beta-2 agonists to protect the airways against bronchoconstrictor stimuli and to promote bronchodilatation may be partially lost with time following long-term use. The long-term use of beta-2 agonist is associated with an increased incidence of asthma exacerbations and other markers of morbidity and mortality. In this article, we try to address some of the current controversies as well as propose various mechanisms behind beta-2 agonist induced morbidity and mortality in asthmatic patients. On the basis of this article, we recommended that clinicians have to refine the use of beta-2 agonists in asthma management guidelines to avoid the beta-2 agonists induced asthma exacerbations.
Export Options
About this article
Cite this article as:
Patel Vasanti, Patel Dipika, Patel Natvarbhai and Gohil Priyanshee, Beta-2 Agonists in Asthma: Medicine or Murderer?, Current Respiratory Medicine Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339808785161323
DOI https://dx.doi.org/10.2174/157339808785161323 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Two Faces of Iminoalditols: Powerful Inhibitors Trigger Glycosidase Activation
Current Enzyme Inhibition Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Update on the Evaluation and Management of Brief Resolved Unexplained Events (Previously Apparent Life-Threatening Events)
Reviews on Recent Clinical Trials Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease
Current Hypertension Reviews The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Oxidative stress and myocarditis
Current Pharmaceutical Design Cardiovascular Drugs Inducing QT Prolongation: Facts and Evidence
Current Drug Safety Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery